Vanguard Group Inc. Buys 163,556 Shares of Medtronic PLC $MDT

Vanguard Group Inc. boosted its stake in shares of Medtronic PLC (NYSE:MDT) by 0.1% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 127,072,962 shares of the medical technology company’s stock after acquiring an additional 163,556 shares during the period. Vanguard Group Inc. owned 0.10% of Medtronic worth $12,102,429,000 at the end of the most recent reporting period.

Other institutional investors have also recently modified their holdings of the company. Delos Wealth Advisors LLC bought a new position in shares of Medtronic in the second quarter worth $27,000. Corundum Trust Company INC acquired a new stake in Medtronic during the third quarter worth about $27,000. Valley Wealth Managers Inc. acquired a new stake in Medtronic during the third quarter worth about $29,000. Steigerwald Gordon & Koch Inc. bought a new position in Medtronic in the 3rd quarter valued at about $33,000. Finally, Tripletail Wealth Management LLC acquired a new position in shares of Medtronic in the 3rd quarter valued at approximately $34,000. 82.06% of the stock is currently owned by institutional investors.

Trending Headlines about Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: FDA cleared Medtronic’s Stealth AXiS system — an integrated planning, navigation and robotics platform for spine surgery that expands the company’s procedural addressable market and supports hardware/software recurring revenue potential. This is a material product‑launch catalyst for spine and future cranial/ENT applications. PR Newswire
• Positive Sentiment: Independent coverage and price‑target lifts: Barclays initiated coverage with an Overweight and $116 PT, and Needham upgraded to Buy with a $121 PT — both signal analyst conviction that recent product momentum and margins support upside from current levels. Benzinga Needham Upgrade
• Positive Sentiment: Market commentary highlights improving returns/operational momentum that could support multiple expansion if sustained — a constructive narrative for longer‑term investors. Yahoo Finance
• Neutral Sentiment: Q3 FY2026 earnings preview: analysts outline what to watch in the upcoming report (revenue cadence, procedure volumes, and guidance) — an event that could be a short‑term catalyst but not new information. MSN Earnings Preview
• Neutral Sentiment: Dividend/income writeups underscore MDT’s ~2.8% yield and ways to generate cash flow; supportive for income investors but a limited driver of near‑term price moves. Benzinga Dividend
• Negative Sentiment: Geopolitical and China exposure risks: analysis highlights tariffs and China’s volume‑based procurement (VBP) program as potential headwinds to margins and growth in a key market — a meaningful downside risk that can compress near‑term revenue and investor sentiment. Seeking Alpha

Medtronic Stock Performance

NYSE:MDT opened at $99.57 on Monday. The stock’s 50-day moving average is $99.28 and its 200-day moving average is $96.46. Medtronic PLC has a 1-year low of $79.55 and a 1-year high of $106.33. The company has a current ratio of 2.42, a quick ratio of 1.80 and a debt-to-equity ratio of 0.57. The stock has a market cap of $127.65 billion, a P/E ratio of 26.84, a price-to-earnings-growth ratio of 2.62 and a beta of 0.71.

Medtronic (NYSE:MDT) last posted its earnings results on Tuesday, November 18th. The medical technology company reported $1.36 EPS for the quarter, topping the consensus estimate of $1.31 by $0.05. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The business had revenue of $8.96 billion for the quarter, compared to the consensus estimate of $8.86 billion. During the same period last year, the company earned $1.26 EPS. The firm’s revenue was up 6.6% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities research analysts anticipate that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, January 16th. Investors of record on Friday, December 26th were given a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a yield of 2.9%. The ex-dividend date of this dividend was Friday, December 26th. Medtronic’s dividend payout ratio (DPR) is currently 76.55%.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on MDT shares. JPMorgan Chase & Co. lifted their price objective on shares of Medtronic from $90.00 to $100.00 and gave the company a “neutral” rating in a research note on Thursday, November 13th. Daiwa Securities Group raised their target price on Medtronic from $104.00 to $117.00 and gave the company a “buy” rating in a report on Tuesday, November 25th. Robert W. Baird set a $103.00 price objective on Medtronic in a research report on Tuesday, December 16th. CICC Research began coverage on Medtronic in a research report on Friday, January 30th. They issued an “outperform” rating on the stock. Finally, Piper Sandler reissued a “neutral” rating on shares of Medtronic in a report on Monday, January 5th. Sixteen research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $111.21.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).